Literature DB >> 18331241

A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis.

Jill K J Gaidos1, Bruce E Hillner, Arun J Sanyal.   

Abstract

OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) is an increasingly prevalent clinical syndrome reflecting a mixture of pathological liver histology with the potential to progress to cryptogenic cirrhosis. Liver biopsy (LB) is the only way to determine the severity of disease. However, LB is invasive, has complications and financial costs. The aim of this study is to determine the benefits of early LB for diagnosis and early treatment.
METHODS: A decision tree model tracked the potential outcomes of NAFLD between an LB-directed approach vs. no initial LB. Each specific biopsy category determined subsequent care actions. The baseline probabilities were determined by literature review and expert opinion.
RESULTS: An initial LB strategy was projected to have a lower mortality compared with the no initial LB group and fewer transplant eligible patients after 5 years. If the prevalence of NAFLD is increased, the mortality increases in both the study groups. With improved efficacy of medical and/or surgical intervention, the mortality rate was decreased.
CONCLUSION: This decision tree model provides a context for balancing the risk and benefit of LB in NAFLD. With early biopsy, and early intervention, the relative return of preventing advanced liver disease per LB was high.

Entities:  

Mesh:

Year:  2008        PMID: 18331241     DOI: 10.1111/j.1478-3231.2008.01693.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  21 in total

1.  Evaluation of Nonalcoholic Fatty Liver Disease in C57BL/6J Mice by Using MRI and Histopathologic Analyses.

Authors:  Jae-Eun Ryu; Woori Jo; Hyun-Ji Choi; Sungwoong Jang; Hyo-Ju Lee; Dong-Cheul Woo; Jeong Kon Kim; Kyung Won Kim; Eun Sil Yu; Woo-Chan Son
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

2.  Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography.

Authors:  Jun Chen; Jayant A Talwalkar; Meng Yin; Kevin J Glaser; Schuyler O Sanderson; Richard L Ehman
Journal:  Radiology       Date:  2011-04-01       Impact factor: 11.105

3.  Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis.

Authors:  An Tang; Justin Tan; Mark Sun; Gavin Hamilton; Mark Bydder; Tanya Wolfson; Anthony C Gamst; Michael Middleton; Elizabeth M Brunt; Rohit Loomba; Joel E Lavine; Jeffrey B Schwimmer; Claude B Sirlin
Journal:  Radiology       Date:  2013-02-04       Impact factor: 11.105

4.  MR quantitative biomarkers of non-alcoholic fatty liver disease: technical evolutions and future trends.

Authors:  Guido Ligabue; Giulia Besutti; Riccardo Scaglioni; Chiara Stentarelli; Giovanni Guaraldi
Journal:  Quant Imaging Med Surg       Date:  2013-08

Review 5.  Role of liver biopsy in nonalcoholic fatty liver disease.

Authors:  I L Ke Nalbantoglu; Elizabeth M Brunt
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

6.  MR Elastography of Liver Disease: State of the Art.

Authors:  Jun Chen; Meng Yin; Kevin J Glaser; Jayant A Talwalkar; Richard L Ehman
Journal:  Appl Radiol       Date:  2013-04

7.  Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression.

Authors:  Masashi Miyao; Hirokazu Kotani; Tokiko Ishida; Chihiro Kawai; Sho Manabe; Hitoshi Abiru; Keiji Tamaki
Journal:  Lab Invest       Date:  2015-07-27       Impact factor: 5.662

8.  Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease.

Authors:  An Tang; Ajinkya Desai; Gavin Hamilton; Tanya Wolfson; Anthony Gamst; Jessica Lam; Lisa Clark; Jonathan Hooker; Tanya Chavez; Brandon D Ang; Michael S Middleton; Michael Peterson; Rohit Loomba; Claude B Sirlin
Journal:  Radiology       Date:  2014-09-22       Impact factor: 11.105

9.  Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies.

Authors:  A Katrina Loomis; Shaum Kabadi; David Preiss; Craig Hyde; Vinicius Bonato; Matthew St Louis; Jigar Desai; Jason M R Gill; Paul Welsh; Dawn Waterworth; Naveed Sattar
Journal:  J Clin Endocrinol Metab       Date:  2015-12-16       Impact factor: 5.958

10.  Non alcoholic fatty liver disease and metabolic syndrome.

Authors:  P Paschos; K Paletas
Journal:  Hippokratia       Date:  2009-01       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.